Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

Reclassification of Ascertain (ASTX727-02) Myelodysplastic Syndrome (MDS) Patients: Outcomes Including Clinical Response, Overall Survival (OS), and Leukemia Free Survival (LFS) Based on IPSS-R and IPSS-M Scoring Systems

Blood (2023) 142 (Supplement 1): 4619.

https://doi.org/10.1182/blood-2023-188258

Published: 2023

Journal Articles

Safety and efficacy of CPX-351 in younger patients (<60 years old) with secondary acute myeloid leukemia

Amanda Przespolewski, Aaron D. Goldberg, Chetasi Talati, Salman Fazal, Pankit Vachhani, Srinivasa R. Sanikommu, Swapna Thota, Julian Waksal, Brian Ball, Christopher Famulare, Maximilian Stahl, Jeffrey Baron, Elizabeth A. Griffiths, James E. Thompson, Kendra Sweet, Eunice S. Wang

Blood (2023) 141 (12): 1489–1493.

https://doi.org/10.1182/blood.2022016678

Published: 2023

Includes: Supplemental data

Journal Articles

Prolonged Survival in Bi-Allelic TP53 -Mutated ( TP53 mut) MDS Subjects Treated with Oral Decitabine/Cedazuridine in the Ascertain Trial (ASTX727-02)

Blood (2022) 140 (Supplement 1): 2066–2069.

https://doi.org/10.1182/blood-2022-163841

Published: 2022

Journal Articles

Safety and Efficacy of Fedratinib in Patients with Primary (P), Post-Polycythemia Vera (Post-PV), and Post-Essential Thrombocythemia (Post-ET) Myelofibrosis (MF) Previously Treated with Ruxolitinib: Primary Analysis of the FREEDOM Trial

Vikas Gupta, Abdulraheem Yacoub, Srdan Verstovsek, Ruben Mesa, Claire Harrison, Alessandro M. Vannucchi, Jean-Jacques Kiladjian, H. Joachim Deeg, Salman Fazal, Lynda Foltz, Ryan J. Mattison, Carole B. Miller, Vinod Parameswaran, Patricia Martin-Regueira, Christopher Hernandez, Jia Wang, Moshe Talpaz

Blood (2022) 140 (Supplement 1): 3935–3937.

https://doi.org/10.1182/blood-2022-156669

Published: 2022

Journal Articles

Safety and Tolerability of Fedratinib (FEDR), an Oral Inhibitor of Janus Kinase 2 (JAK2), in Patients with Intermediate- or High-Risk Myelofibrosis (MF) Previously Treated with Ruxolitinib (RUX): Results from the Phase 3b FREEDOM Trial

Vikas Gupta, Abdulraheem Yacoub, Srdan Verstovsek, Ruben A. Mesa, Claire N. Harrison, Giovanni Barosi, Jean-Jacques Kiladjian, H. Joachim Deeg, Salman Fazal, Lynda Foltz, Ryan J. Mattison, Carole B. Miller, Vinod Parameswaran, Vishwanath Gharpure, Christopher Hernandez, Tianhua Wang, Moshe Talpaz

Blood (2021) 138 (Supplement 1): 389.

https://doi.org/10.1182/blood-2021-147607

Published: 2021

Journal Articles

SEL24/MEN1703 Inhibits PIM/FLT3 Downstream Target in Acute Myeloid Leukemia (AML) Patients: Results of the Pharmacodynamics (PD) Assay and Genomic Profiling in the First-in-Human Diamond-01 Trial

Blood (2021) 138 (Supplement 1): 3436.

https://doi.org/10.1182/blood-2021-150277

Published: 2021

Journal Articles

Safety and Efficacy of CPX-351 in Younger Patients < 60 Years Old with Secondary Acute Myeloid Leukemia: An Updated Analysis

Amanda Przespolewski, Aaron D Goldberg, Chetasi Talati, Salman Fazal, Pankit Vachhani, Srinivasa Reddy R. Sanikommu, Swapna Thota, Julian Waksal, Brian Ball, Christopher Famulare, Maximilian Stahl, Zoe Mckinnell, Jeffrey Baron, Elizabeth A. Griffiths, James E. Thompson, Kendra Sweet, Eunice S. Wang

Blood (2021) 138 (Supplement 1): 1264.

https://doi.org/10.1182/blood-2021-153791

Published: 2021

Journal Articles

Intrathecal Chemotherapy As a Potential Alternative Treatment for Steroid-Refractory Immune Effector Cell-Associated Neurotoxicity Syndrome

Urwat Til Vusqa, Palash Asawa, Maitreyee Rai, Yazan Samhouri, Prerna Mewawalla, Anna Koget, Santhosh Sadashiv, Cyrus Kahn, Salman Fazal, John Lister

Blood (2021) 138 (Supplement 1): 4816.

https://doi.org/10.1182/blood-2021-151113

Published: 2021

Journal Articles

Oral Decitabine/Cedazuridine in Patients with Lower Risk Myelodysplastic Syndrome: A Longer-Term Follow-up of from the Ascertain Study

Blood (2021) 138 (Supplement 1): 66.

https://doi.org/10.1182/blood-2021-144648

Published: 2021

Journal Articles

Efficacy of Oral Decitabine/Cedazuridine (ASTX727) in the CMML Subgroup from the Ascertain Phase 3 Study

Blood (2021) 138 (Supplement 1): 3682.

https://doi.org/10.1182/blood-2021-154179

Published: 2021

Journal Articles

Community Versus Academic Practice in Essential Thrombocythemia and Myelofibrosis: Differences in Clinical Characteristics, Diagnosis, Treatment Patterns, and Symptom Burden (Analysis of Data from the MOST Study)

Roger Lyons, David Lessen, Salman Fazal, Robyn Scherber, Patricia Kalafut, Haobo Ren, Ellen Ritchie

Blood (2021) 138 (Supplement 1): 1497.

https://doi.org/10.1182/blood-2021-145909

Published: 2021

Journal Articles

Efficacy of Venetoclax Based Regimens in Relapsed Refractory Multiple Myeloma: A Systematic Review and Meta-Analysis

Laila Hashim, MBBS, Muhammad Salman Faisal, MD MBBS, Zahoor Ahmed, MD, Insija Ilyas Selene, MBBS, Moazzam Shahzad, MD, Syed Maaz Abdullah, MBBS, Yazan Samhouri, MD, Muhammad Yasir, MD, Ahsan Wahab, MD, Hamid Ehsan, MDMBBS, Karun Neupane, MBBS,MD, Faiz Anwer, MD, Salman Fazal, MD

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-142054

Published: 2020

Journal Articles

Role of Hypomethylating Agents in Accelerated and Blast Phase of Philadelphia Negative Myeloproliferative Neoplasms: A Systematic Review

Karun Neupane, MBBS,MD, Muhammad Salman Faisal, MD MBBS, Yazan Samhouri, MD, Israr Khan, Asim Tameez Ud Din, MD MBBS, Zahoor Ahmed, MD, Muhammad Aadil Rahman, MBBS, Ali Younas Khan, MD, Hamid Ehsan, MDMBBS, Vinayak Aryal, MBBS, MD, Syed Maaz Abdullah, MBBS, Abdul Rafae, MD, Faiz Anwer, MD, Salman Fazal, MD

Blood (2020) 136 (Supplement 1): 20–21.

https://doi.org/10.1182/blood-2020-138847

Published: 2020

Journal Articles

Spleen and Symptom Responses of JAK Inhibitors in Myelofibrosis; A Systematic Review of Phase 2 and 3 Trials

Muhammad Ans Sharif, MBBS, Muhammad Salman Faisal, MD MBBS, Yazan Samhouri, MD, Laila Hashim, MBBS, Muhammad Yasir, MD, Muhammad Yasir Anwar, Ali Younas Khan, MD, Moazzam Shahzad, MD, Anum Javaid, MD, Muhammad Aadil Rahman, MBBS, Faiz Anwer, MD, Salman Fazal, MD

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-140131

Published: 2020

Journal Articles

The Role of Checkpoint Inhibitors in Adults with Classical Hodgkin Lymphoma; A Systematic Review and Meta-Analysis of Phase II and III Clinical Trials

Yazan Samhouri, MD, Muhammad Yasir Anwar, Ali Younas Khan, MD, Urwat Til Vusqa, MD, Iqraa Ansar, MDMBBS, Muhammad S. Anil, MD, Lynna Alnimer, MD, Taha Sheikh, MDMPH, Muhammad Aslam Khan, MD, Faiz Anwer, MD, Salman Fazal, MD, John Lister, MD

Blood (2020) 136 (Supplement 1): 25–26.

https://doi.org/10.1182/blood-2020-140591

Published: 2020

Journal Articles

Clinical Efficacy and Safety of Oral Decitabine/Cedazuridine in 133 Patients with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-133855

Published: 2020

Journal Articles

Selection of Treatment and Survival in Patients with Gray Zone Lymphoma; A Comprehensive Population-Based Analysis

Yazan Samhouri, MD, Thejus Jayakrishnan, MBBS, Lynna Alnimer, MD, Deanna Huffman, DO, Veli Bakalov, MD, Rodney E Wegner, MD, Salman Fazal, MD, Cyrus Kahn, MD, John Lister, MD

Blood (2020) 136 (Supplement 1): 44–45.

https://doi.org/10.1182/blood-2020-137317

Published: 2020

Journal Articles

Patterns of Treatment and Survival in Elderly Patients with Primary CNS Lymphoma; An 11-Year Population-Based Analysis

Yazan Samhouri, MD, Moaath Mustafa Ali, MD MPH, Thejus Jayakrishnan, MBBS, Chelsea Peterson, DO, Veli Bakalov, MD, Salman Fazal, MD, Cyrus Kahn, MD, Rodney E Wegner, MD, John Lister, MD

Blood (2020) 136 (Supplement 1): 2–3.

https://doi.org/10.1182/blood-2020-137300

Published: 2020

Journal Articles

Predictors and Long Term Outcomes for DLBCL Patients Undergoing Surgery Prior to Systemic Therapy

Thejus Jayakrishnan, MBBS, Yazan Samhouri, MD, Veli Bakalov, MD, Zena Chahine, MD, Rodney E Wegner, MD, Cyrus Khan, MD, Salman Fazal, MD, John Lister, MD

Blood (2020) 136 (Supplement 1): 11.

https://doi.org/10.1182/blood-2020-137827

Published: 2020

Journal Articles

Hematological Complications of Donor Origin Following Allogeneic Hematopoietic Stem Cell Transplantation

Ahmed Khattab, MD, Sunita Patruni, MD, Gina Berteotti, Thejus Jayakrishnan, MBBS, Salman Fazal, MD, John Lister, MD

Blood (2020) 136 (Supplement 1): 34.

https://doi.org/10.1182/blood-2020-140084

Published: 2020

NARROW

Reclassification of Ascertain (ASTX727-02) Myelodysplastic Syndrome (MDS) Patients: Outcomes Including Clinical Response, Overall Survival (OS), and Leukemia Free Survival (LFS) Based on IPSS-R and IPSS-M Scoring Systems

Safety and efficacy of CPX-351 in younger patients (<60 years old) with secondary acute myeloid leukemia

Prolonged Survival in Bi-Allelic TP53 -Mutated ( TP53 mut) MDS Subjects Treated with Oral Decitabine/Cedazuridine in the Ascertain Trial (ASTX727-02)

Safety and Efficacy of Fedratinib in Patients with Primary (P), Post-Polycythemia Vera (Post-PV), and Post-Essential Thrombocythemia (Post-ET) Myelofibrosis (MF) Previously Treated with Ruxolitinib: Primary Analysis of the FREEDOM Trial

Safety and Tolerability of Fedratinib (FEDR), an Oral Inhibitor of Janus Kinase 2 (JAK2), in Patients with Intermediate- or High-Risk Myelofibrosis (MF) Previously Treated with Ruxolitinib (RUX): Results from the Phase 3b FREEDOM Trial

SEL24/MEN1703 Inhibits PIM/FLT3 Downstream Target in Acute Myeloid Leukemia (AML) Patients: Results of the Pharmacodynamics (PD) Assay and Genomic Profiling in the First-in-Human Diamond-01 Trial

Safety and Efficacy of CPX-351 in Younger Patients < 60 Years Old with Secondary Acute Myeloid Leukemia: An Updated Analysis

Intrathecal Chemotherapy As a Potential Alternative Treatment for Steroid-Refractory Immune Effector Cell-Associated Neurotoxicity Syndrome

Oral Decitabine/Cedazuridine in Patients with Lower Risk Myelodysplastic Syndrome: A Longer-Term Follow-up of from the Ascertain Study

Efficacy of Oral Decitabine/Cedazuridine (ASTX727) in the CMML Subgroup from the Ascertain Phase 3 Study

Community Versus Academic Practice in Essential Thrombocythemia and Myelofibrosis: Differences in Clinical Characteristics, Diagnosis, Treatment Patterns, and Symptom Burden (Analysis of Data from the MOST Study)

Efficacy of Venetoclax Based Regimens in Relapsed Refractory Multiple Myeloma: A Systematic Review and Meta-Analysis

Role of Hypomethylating Agents in Accelerated and Blast Phase of Philadelphia Negative Myeloproliferative Neoplasms: A Systematic Review

Spleen and Symptom Responses of JAK Inhibitors in Myelofibrosis; A Systematic Review of Phase 2 and 3 Trials

The Role of Checkpoint Inhibitors in Adults with Classical Hodgkin Lymphoma; A Systematic Review and Meta-Analysis of Phase II and III Clinical Trials

Clinical Efficacy and Safety of Oral Decitabine/Cedazuridine in 133 Patients with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)

Selection of Treatment and Survival in Patients with Gray Zone Lymphoma; A Comprehensive Population-Based Analysis

Patterns of Treatment and Survival in Elderly Patients with Primary CNS Lymphoma; An 11-Year Population-Based Analysis

Predictors and Long Term Outcomes for DLBCL Patients Undergoing Surgery Prior to Systemic Therapy

Hematological Complications of Donor Origin Following Allogeneic Hematopoietic Stem Cell Transplantation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only